Abstract:Objective:To investigate the expression of pre-B-cell leukemia homeobox 3 (PBX3) and the phosphatase and tensin homology deleted on chromosome 10 (PTEN) in cervical cancer and its relationship with the clinicopathologic characteristics and prognosis.Methods:Cervical cancer tissues and adjacent tissues of 85 patients with cervical cancer admitted to Xianlin Gulou Hospital from June 2014 to December 2018 were collected and the expression levels of PBX3 and PTEN were detected by immunohistochemistry. The univariate analysis and Logistic regression model were used to analyze the relationship between the expression levels of PBX3, PTEN and clinicopathologic features. Kaplan-Meier survival curve was used to analyze the relationship between the expression levels of PBX3, PTEN and prognosis.Results:The positive expression rate of PBX3 protein in cervical cancer tissues was higher than that in adjacent tissues: 38.82%(33/85) vs. 25.53%(20/85); the positive expression rate of PTEN protein was lower than that in adjacent tissues: 36.47%(31/85) vs. 98.82%(84/85), and there were significant differences ( P<0.05). The univariate analysis showed that the expression levels of PBX3 and PTEN were associated with clinical stages, degree of tumor differentiation, lymph node metastasis, vascular invasion, and degree of tumor invasion ( P<0.05). The multiple Logistic regression model showed that the clinical stages, tumor differentiation and lymph node metastasis were independent influencing factors for the positive expression of PBX3 or PTEN in cervical cancer tissues ( P<0.05). While 45.45%(15/33) of patients with positive PBX3 expression died, with a median survival of 31 months, and 25.00% (13/52)of patients with negative expression died, with a median survival of 38 months. Kaplan-rank test showed that the survival time in the patients with positive PBX3 expression and in the patients with negative expression had significant difference ( P=0.025). While 22.58%(7/31) of patients with positive PTEN expression died, with a median survival of 39 months, and 38.89%(21/54) of the patients with negative expression died, with a median survival time of 33 months. Kaplan-rank test showed that the survival time in the patients with positive PTEN expression and in the patients with negative expression had significant difference ( P=0.035). Conclusions:The expression of PBX3 is up-regulated and PTEN is down-regulated in cervical cancer. The expression levels of PBX3 and PTEN are related to clinical stage, tumor differentiation and lymph node metastasis. The prognosis of the patients with positive PBX3 expression is worse than that of the patients with negative expression, and the prognosis of the patients with positive PTEN expression is better than that of the patients with negative expression.

Expression of TBX3 and the Correlations with P53、PS2 in Luminal Breast Cancer

TOX3 as a novel biomarker in luminal B breast cancer.

The Expression and Clinical Significance of TBX3 Gene in Different Molecular Subtypes of Breast Cancer

Correlations Between P53 Expression and Clinicopathologic Factors and the Prognosis of Luminal Breast Cancer

Relationship of EZH2 and p53 Expression with Pathological Characteristics of TNBC Patients

Correlation of p53 expression with triple negative breast cancer and its prognosis:a meta analysis

Expression of C-Erbb-2,p53,pcna and Nm23 Proteins in Breast Cancer and Their Clinical Significance

Expression and Significance of Ki-67 and p53 in Triple Negative Breast Cancer

Evaluation of Nm23,c-Erbb-2 and P53 Gene Expressions in Multivariable Analysis of Breast Cancer Prognosis

A Study on Pertinence of Pathologic and Biology Features in HER-2, ER and PR Negative Breast Cancer

Expression Correlation of Ki67 to P53,VEGF,and C-erbB-2 Genes in Breast Cancer and Their Clinical Significances

The expression of pre-B-cell leukemia homeobox 3and phosphatase and tensin homology deleted on chromosome 10in cervical cancer and its relationship with clinicopathologic features and prognosis

Expression Comparison and Clinical Significance of PD-L1 (22C3) and PD-L1 (SP142) in Triple Negative Breast Cancer

[P53 Protein Expression in HER2-negative Breast Invasive Ductal Carcinoma].

Expression and clinical significance of HER3 in breast carcinoma tissue

Analysis and Clinical Significance of ER PR Ki67 and P53 Expression in Breast Cancer

Prognostic Significance of CD117 Expression and TP53 Missense Mutations in Triple-Negative Breast Cancer

Expressions of P53, Nm23, Bcl-2 in Bladder Transitional Cell Carcinoma and Its Clinical Significance

Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics

Expression of TBX3 Is Correlated with Tumor Proliferation and Invasion in Non-small Cell Lung Cancer

Expressions of P53 and Bcl-2 in Pancreatic Carcinoma and Its Clinical Significance